Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-23
DOI
10.1038/s41598-020-67199-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
- (2019) Anna Yordanova et al. CLINICAL NUCLEAR MEDICINE
- The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours
- (2019) Aldo Scarpa ANNALES D ENDOCRINOLOGIE
- Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
- (2019) Samuel Adant et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
- (2018) Tobias Hofving et al. ENDOCRINE-RELATED CANCER
- Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
- (2018) Nupur K. Purohit et al. Oncotarget
- A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors
- (2018) Chester E. Chamberlain et al. MOLECULAR CANCER THERAPEUTICS
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line
- (2017) Jacob J. Henderson et al. PEDIATRIC BLOOD & CANCER
- Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
- (2017) Paul Lesueur et al. Oncotarget
- The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors
- (2017) Lisa Bodei et al. Journal of Thoracic Disease
- Upregulation of Key Molecules for Targeted Imaging and Therapy
- (2016) V. F. Taelman et al. JOURNAL OF NUCLEAR MEDICINE
- Origin of the U87MG glioma cell line: Good news and bad news
- (2016) Marie Allen et al. Science Translational Medicine
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
- (2016) Julie Nonnekens et al. Theranostics
- The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
- (2015) Seong-Jang Kim et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
- (2014) G. Kong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
- (2014) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion
- (2013) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
- (2013) Michael S. Hofman et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET/CT
- (2013) Roderick J. Clifton-Bligh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
- (2013) F. Al-Ejeh et al. JOURNAL OF NUCLEAR MEDICINE
- PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy
- (2013) Jeremy P.H. Chow et al. MOLECULAR CANCER THERAPEUTICS
- The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
- (2012) Mike De Vos et al. BIOCHEMICAL PHARMACOLOGY
- Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
- (2012) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Hypersensibilité à la radiothérapie chez un patient atteint de la sclérose tubéreuse de Bourneville : réflexions biologiques à partir d’un cas clinique
- (2012) B. Duchemain et al. Cancer Radiotherapie
- Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
- (2012) Linda Villard et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of 131I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter
- (2012) A. G. McCluskey et al. JOURNAL OF NUCLEAR MEDICINE
- Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies
- (2012) Eva Forssell-Aronsson et al. NEUROENDOCRINOLOGY
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
- (2011) J. M. Senra et al. MOLECULAR CANCER THERAPEUTICS
- Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
- (2011) R.J. Hicks CANCER IMAGING
- Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set
- (2010) David S. Klimstra et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
- (2010) Daniel Hubble et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
- (2010) Dik J. Kwekkeboom et al. SEMINARS IN NUCLEAR MEDICINE
- High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
- (2009) Grace Kong et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
- (2009) J. P. Palma et al. CLINICAL CANCER RESEARCH
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- (2009) Dik J Kwekkeboom et al. ENDOCRINE-RELATED CANCER
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
- (2008) Martijn van Essen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
- Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks
- (2008) X. Liu et al. MOLECULAR CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More